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Abstract
Viral outbreaks have become significant threats to global human public health. 
New emerging viruses, pathogen mutations, and even the progressive loss of 
efficacy in some existing vaccines are behind this problem, which is amplified by 
the rapid virus spread given the ease of current mobility. Taking into account that 
these outbreaks arise in the absence of conventional effective vaccines, alternative 
approaches based on trained (innate) immunity are being considered. This immu-
nity is dependent on a functional reprogramming of innate immune cells, leading to 
an enhanced nonspecific response towards different pathogens, including viruses. 
Trained immunity-based vaccines (TIbVs), defined as vaccine formulations con-
taining trained immunity inducers, could be used during viral outbreaks to confer 
non-specific protection but also to enhance adaptive specific immune responses. 
In this chapter, we aim to illustrate how TIbVs could tackle the above-mentioned 
situations derived from viral outbreaks, reviewing the potential of available TIbVs 
in such urgent situations with a special mention to COVID-19.
Keywords: trained immunity-based vaccines, innate immune training, pandemic, 
viral outbreak, BCG, MV130
1. Introduction
Pandemics and epidemics of infectious origin are large-scale outbreaks that 
can greatly increase morbidity and mortality globally or over a wide geographic 
area, respectively [1]. Pandemics have occurred throughout history and appear to 
be increasing in frequency in the last centuries. Noteworthy examples include the 
Black Death at the end of the Middle Ages, Spanish flu in 1918, the 2014 West Africa 
Ebola epidemic or the current COVID-19 pandemic. The direct impact of pandem-
ics on health can be dramatic. These large outbreaks can disproportionally affect 
younger or active workers, but vulnerable populations such as the elderly are at a 
particular high-risk. Pandemics can cause acute, short-term as well as longer-term 
damage to economic growth due to public health efforts, health system expendi-
tures, and aid to affected sectors. Evidence suggests that epidemics and pandemics 
can have significant social and political consequences too, by debilitating institu-
tions, amplifying political tensions, stigmatizing minority populations, or encour-
aging sharp differences between social classes [2].
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Outbreaks by respiratory ribonucleic acid (RNA) viruses such as influenza 
or coronaviruses entail the principal threat due to their ease of spreading among 
humans, their potential severity and recurrence. However, other RNA viruses 
such as flaviviruses (Zika) or filoviruses (Ebola) must be taken into consideration 
due to a great overall burden of morbidity and mortality [3]. Antiviral drugs can 
help mitigate a viral outbreak by reducing the disease in infected patients or their 
infectiousness. While these drugs can be very successful against some viruses (e.g. 
hepatitis C virus [HCV]) [4], they are not universally effective as exemplified in 
the current SARS-CoV-2 pandemic [5]. Nowadays, having effective vaccines may be 
the only tool to reduce susceptibility to infection and thus, prevent the rate of virus 
spread [2].
Vaccination has dramatically decreased the burden of infectious diseases. 
Vaccines have saved hundreds of millions of lives over the years [6]. It has been esti-
mated that approximately 103 million cases of childhood diseases were prevented in 
the United States through vaccination between 1924 and 2010 [7]. The eradication 
of smallpox in 1980 through vaccination is considered one of the crown accom-
plishments of medicine. Despite these achievements, effective vaccines have been 
developed against just over 30 pathogens among bacteria and viruses. There are 
many pathogens, including viruses such as human immunodeficiency virus (HIV) 
or respiratory syncytial virus (RSV), for which all efforts for vaccine development 
have failed so far. In addition, current available vaccines for worldwide important 
viral diseases like influenza are suboptimal, especially in the elderly, resulting in 
vulnerability among billions of at-risk populations [6]. On the other hand, having a 
new effective and safe vaccine in time to control highly contagious emerging viruses 
that cause epidemic or pandemic threats is an almost impossible task considering 
the timeframes for vaccine development. This includes preclinical and clinical 
research, its approval by the regulatory authorities, as well as its production and 
distribution [3].
Altogether, it has been postulated that one possibility of filling the gap between 
the appearance of a viral outbreak by an emerging pathogen and the availability of a 
specific vaccine is to take advantage of the heterologous protection of some existing 
vaccines, in order to increase the non-specific resistance of the host through trained 
immunity [8, 9].
2. Specific anti-infectious vaccines
Conventional (specific) anti-infectious vaccines are biological preparations 
containing live-attenuated or dead microorganisms, their antigens or nucleic acids 
encoding for them, designed for specific pathogens. The purpose of vaccination 
is to induce a long lasting adaptive immune response against key antigens able to 
confer host resistance for future encounters with the corresponding pathogen. 
Either the production of antibodies, generation of T helper/effector cells, or both, 
may play a critical role in such a resistance, which greatly depends on the type of 
pathogen, the route of entrance and the host-pathogen relationship (e.g., extracel-
lular and/or intracellular) [10]. Successful vaccines are highly effective not only 
in inducing long-lasting immunity against disease-causing pathogens, but also in 
providing herd immunity to the community that substantially restricts the spread 
of infection [6].
Most of the vaccines available today have been developed empirically and used 
successfully long before their mechanism of action on the immune system was 
understood. Early protection is associated to induction of antigen-specific antibod-
ies, being their quality (avidity, specificity, or neutralizing capacity) key factors for 
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their efficacy. Long-term protection relies on the persistence of vaccine antibodies 
and availability of immune memory cells capable of rapid and effective reactivation 
with subsequent microbial exposure. On the other hand, T cells have a critical role 
in the induction of high affinity antibodies and immune memory. Furthermore, 
T cells have a direct role in protection conferred by some vaccines, including the 
tuberculosis Bacille Calmette-Guérin (BCG) vaccine [11].
Vaccines using whole pathogens have been classically classified as either live 
attenuated or inactivated (killed). Subunit vaccines contain just selected antigens 
(e.g., proteins, polysaccharides). Recently, due to a growing availability of bioinfor-
matics and sequencing tools, there has been an increase interest on so-called “ratio-
nal” vaccine design approaches for subunit vaccines, such as the reverse vaccinology 
[12]. In this regard, modern vaccines include recombinant proteins or nucleic acids 
[13]. Rather than administering the antigen itself, DNA and mRNA vaccines target-
ing dendritic cells (DCs) encode the antigen of interest that will be produced by the 
vaccinated host, representing a new era in vaccinology [14]. In fact, the first RNA 
vaccine licensed for humans in Western countries has been recently developed for 
SARS-CoV-2.
As commented before, a vaccine response is linked to the induction of T and 
B cell specific responses to the antigens contained in the vaccine. This requires 
lymphocyte activation, proliferation and differentiation on specialized lymphoid 
tissues (e.g lymph nodes), where antigen presenting cells, like DCs for T cells or 
follicular dendritic cells (FDCs) for B cells, are present. Mature DCs are recruited 
into the T cell areas of lymph nodes from the periphery, e.g., at the site of injection 
of the vaccine. DCs express pattern recognition receptors (PRR) that recognize 
evolutionary conserved pathogen-associated molecular patterns (PAMPs) that are 
not contained in self-antigens and are identified as “danger signals” [15]. When 
immature DCs are exposed to the vaccine-derived antigens at the site of vaccina-
tion, they uptake them and become activated [16]. This activation will lead to their 
maturation with the expression of homing receptors at their surface, triggering DC 
migration to the draining lymph node through afferent lymphatic vessels, where 
the activation of T and B lymphocytes will occur. Mature DCs process the up-taken 
antigens and present them to naïve T cells associated to molecules of the major 
histocompatibility complex (MHC) within the T cell areas of lymph nodes. On the 
other hand, unprocessed native antigens, either free or complexed with antibod-
ies or complement, access the B cell areas of lymph nodes (lymphoid follicles) 
where they are captured by FDCs and displayed from their cell surface to the B 
cells. Antigen-specific B cells will rapidly proliferate forming a germinal center 
and differentiate into plasma cells producing low-affinity immunoglobulin (Ig) M 
antibodies. The B cells will then receive additional signals from activated T cells, 
undergoing isotype antibody switch from IgM to IgG or IgA and affinity maturation 
of the antibodies produced.
For a vaccine to be immunogenic enough, DC activation, that can be achieved by 
adjuvants, is essential. Live attenuated and inactivated whole-cell vaccines are consid-
ered “self-adjuvanted” as they naturally present sufficient PAMPs to activate innate 
immune cells, including DCs; thus, promoting a robust antigen-specific immune 
response. In contrast, subunit vaccines generally require different types of adjuvants 
to enhance and/or drive the immune response in the desired  direction [15, 17].
2.1 Difficulties for novel specific vaccines in a viral outbreak situation
Viral outbreaks appear when there is a sufficient number of susceptible individuals 
within a nearby population. Although susceptibility is a balance between host factors 
(high/low resistance) and pathogens (high/low virulence), in many cases it reflects a 
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lack of prior contact with a given pathogen. In general, this is related to the emergence 
of new viruses or the lack of effective vaccines against known viruses. As pointed 
above, the development of effective vaccines is not an easy task against certain viruses. 
We are still lacking vaccines for some of the most lethal viral infections, including 
HIV and MERS-CoV, among others. These pathogens are difficult to tackle, as we do 
not fully understand their mechanisms to evade the immune system or how to elicit 
protective immunity against them [13]. However, encouraging progress is being made 
against these pathogens and there are currently several “pipeline vaccines” in devel-
opment, such as RSV, universal influenza vaccine, and SARS-CoV-2 [18–20]. Apart 
of SARS-CoV-2 for obvious reasons in the current pandemic, there is an urgency to 
have a universal influenza vaccine that provides a broad and durable protection from 
influenza virus infection. Yet, the high level of antigenic diversity and variability, and 
antigenic drift in the surface antigens, enable these viruses to escape antibody-medi-
ating neutralization [21]. On the other hand, there is a number of vaccines currently 
licensed, including the influenza A virus vaccine, that provide incomplete protection, 
especially in high-risk groups [22]. Mumps outbreaks observed in Ireland, United 
Kingdom and United States in vaccinated subjects with Measles Mumps Rubella 
(MMR) vaccine is another example [23]. Different factors have been postulated to 
contribute to mumps outbreak, including waning immunity and primary and second-
ary vaccine failure. Yet, their actual contribution is not fully understood [23].
Vaccine efficacy must consider different target populations as well. Adaptive 
immune response to vaccines may be limited in newborn and the elderly. Early in 
life, immune responses are dampened compared to adults [24, 25]. Neonates have 
underdeveloped germinal centers in lymph nodes and the spleen, and low expres-
sion of B cell receptors which in turn results in low levels of primary IgG responses 
to infections and vaccines [26]. As we age, our immune system undergoes age-
related changes that lead to progressive deterioration of the innate and the adaptive 
immune responses, this is termed immunosenescence. The most common features 
of immunosenescence are short-lived memory responses, impaired response to new 
antigens, increased predisposition to autoimmune diseases and low-grade systemic 
inflammation (inflammaging) [27, 28]. Immunosenesence results in increased 
susceptibility to infections and deficient response to vaccination causing high hos-
pitalization and mortality rates. For example, influenza vaccine efficiency has been 
reported to be 17–53% in the elderly, compared with the 70–90% efficacy in young 
adults [29]; and vaccination with Varicella zoster virus (VZV), also an important 
pathogen in elderly people, only partially prevents reactivation of herpes zoster [27].
If the difficulties listed above are outlined for existing or developing vaccines, 
quickly obtaining an effective vaccine to urgently control a new virus outbreak is 
almost an impossible task in the short-term as pointed above. This is well exemplified 
by the SARS-CoV-2 vaccine race pushed by the devastating COVID-19, with more than 
100 vaccine candidates in the running. It is considered that no less than 1 year will last 
the time until the first licensed vaccine can provide protection in the best scenario [30]. 
This, in spite of greatly shortening the usual clinical development time and regulatory 
obstacles for a new vaccine and, therefore, without knowing its true performance and/
or safety in the medium term compared to other authorized vaccines [31].
3. Trained immunity and infections
It has become evident from epidemiological, clinical and experimental data that 
some conventional whole-cell vaccines, like BCG and others, also provide resistance 
to infectious diseases not related with the specific pathogen targeted by the vaccine 
[32–34]. Much of these non-specific “heterologous” effects appear to depend on 
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the activation of innate immune cells by the PAMPs contained naturally in these 
vaccines [10], although other mechanisms such as cross-reactive epitopes between 
different pathogens could also account for this protection in some cases [35].
Immunological memory, understood as the ability to “remember” past encoun-
ters with pathogens, has been classically attributed to the adaptive branch of the 
immune system exclusively, by virtue of the antigen-driven clonal expansion of 
T and B lymphocytes and exemplified by the mechanism of conventional specific 
vaccines pointed above. However, the notion that innate immunity was unable to 
induce immunological memory has been challenged in recent years, particularly 
from studies in organisms that lack adaptive immunity, such as plants or inverte-
brates, as well as early studies in mice lacking the adaptive immune system [8, 36]. 
Altogether, the term ‘trained immunity’ was coined to define an innate immune 
memory that lead the innate immune system to an enhanced response to secondary 
challenges [37]. Importantly, trained immunity seems to be underlying the heter-
ologous effects of an increasing number of vaccines [38–40].
3.1 The concept
What is trained immunity? - Trained immunity is defined as the memory of the 
innate immune system, where an encounter with a first stimulus (e.g. a microbial 
insult) results in a subsequent long-term adaptation and enhanced non-specific 
response by innate immune cells against a secondary challenge (the same or unre-
lated), thus providing non-specific, broad-spectrum, long-term protection in case 
of infection [8, 9, 37, 41].
Which cells can be trained? - Trained immunity properties have been defined for 
distinct cell subsets of the innate immune system [9, 42], including natural killer 
(NK) cells and innate lymphoid cells [43]. Of note, training of myeloid cells [42], 
particularly monocytes and macrophages [44, 45], and more recently DCs [46, 47] 
and hematopoietic stem cells [48], have been extensively studied. Finally, the 
acquisition of this immunological memory has also been demonstrated to a lesser 
extent for non-immune cells [49].
How to get trained? - A wide variety of stimuli can train innate immune cells, 
particularly when considering monocytes and macrophages [9, 50]. Among 
infectious agents, live microorganisms such as the tuberculosis vaccine BCG [51], 
Candida spp [52] or viruses [53, 54]; bacterial components, such as flagellin, 
lipopolysaccharide, muramyl dipeptide [55], fungal components as β-glucan [52] or 
even helminth products [56]. In general, microbial ligands engaging some PRR, like 
C-type lectin receptors (CLRs), nucleotide-binding oligomerization domain-like 
receptors (NLRs) are well established training inducers, whereas those engaging 
toll-like receptors (TLRs) may have opposite effects depending on the TLR type and 
concentration [55, 57]. Intriguingly, not only infectious agents but also endogenous 
inducers and metabolites such as oxidized low-density lipoprotein or mevalonate 
can induce trained immunity [50].
What hallmarks define trained immunity? - In contrast to adaptive immune 
responses, epigenetic reprogramming of transcriptional pathways — rather than 
gene recombination — mediates trained immunity. This training phenomenon com-
prises three key hallmarks that occur at the intracellular level: increased cytokine 
production upon rechallenge, changes in the metabolism and epigenetic reprogram-
ming [9, 58, 59], which eventually support increased protection upon infection.
Among those cytokines whose production is augmented after re-exposure in 
trained cells, proinflammatory molecules such as tumor necrosis factor α (TNF-α), 
interleukin (IL)-6, IL-1β and interferon γ (IFN-γ) are fairly constant [45, 52, 55, 
60, 61]. Modulation of IL-10 varies between studies [45, 52, 56, 62, 63]. A noted 
Viral Outbreaks
6
shift from oxidative phosphorylation to aerobic glycolysis (Warburg effect) is the 
main change in cellular metabolism during the induction trained immunity [64]. 
Moreover, glutaminolysis, cholesterol synthesis and the tricarboxylic acid cycle 
are non-redundant pathways required for trained immunity to take place [64, 65]. 
Epigenetic reprogramming, mainly mediated by histone modifications, is one of the 
bases for the long-lasting effect of trained immunity [8, 66–68]. Immune pathway 
activation and changes in metabolism serve as basis for epigenetic rewiring [65]. As a 
result, epigenetic modifications have been found at the level of important promoters 
for the training process, which makes chromatin more accessible and conditions gene 
expression patterns of trained cells upon stimulation with a secondary  challenge [69].
As a result of the whole process, enhanced, broad-spectrum, non-specific 
protection mediated by innate immune cells is found upon infection. This cross-
protection has been observed for a wide range of human pathogens including fungi 
[51, 52], parasites [70, 71] and different bacterial infections [72–75]. Importantly, 
induction of trained immunity has been proved to be effective against viral infec-
tions including yellow fever [76], influenza A virus [77] and others [78, 79]. In this 
line, the induction of this phenomenon has been also proposed as a tool for reduc-
ing susceptibility to emergent SARS-CoV-2 infection, as will be described at the end 
of the chapter [78, 80].
How long does trained immunity last? – Trained immunity phenotypes have been 
observed for months and up to one year after the training insult. This was initially 
controversial, as trained immunity properties had been attributed to short-lived 
myeloid cells such as monocytes or DCs [38]. In this regard, several studies have 
shown that modulation of bone marrow progenitors is also an integral component 
of trained immunity, supporting the long-lasting effect of this phenomenon [9, 81]. 
In this way, trained immunity inducers [82–85] would be able to reprogram and 
induce expansion of hematopoietic progenitors with a particular bias to the myeloid 
lineage. Thus, bone marrow-derived mature cells would be also trained [86], show-
ing improved clearance of infection [83].
Complementary to progenitor reprogramming, peripheral trained immunity 
induction would take place in tissue-resident cells [9]. This is especially relevant at 
the mucosal level, where cells encounter most of the infectious training inducers. 
Alveolar macrophage (AM) memory was demonstrated following viral infection 
[87, 88]. Training of these long-living cells led to increase antimicrobial properties, 
independently of systemic immunity [87, 89]. This local training of AM was further 
reproduced following respiratory mucosal administration of tuberculosis vaccine, 
being crucial for Mycobacterium tuberculosis clearance [90]. On the other hand, 
training of NK cells lead to long-lived, self-renewing, stable expanded cells with 
memory-like properties, both in an antigen-dependent or independent manner 
[91–93]. Finally, it was also reported that self-renewing long-living skin epithelial 
stem cells exhibited local trained immunity, providing faster wound healing in 
primed mice than in naïve mice [94, 95].
3.2 Trained immunity on ongoing immune responses
3.2.1 Effect on adaptive immunity
Non-specific effects of vaccines have been extensively studied and reported 
over the last decades. Although trained innate cells could partially account for these 
effects, involvement of adaptive immunity has also been suggested [96]. An adap-
tive immune mechanism of non-specific effects could be heterologous immunity; 
vaccine antigens can give rise to T cell cross-reactivity against other antigens that 
may confer some protection against unrelated pathogens [96, 97].
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However, innate immune cells constitute the bridge between the intrusion of 
microbial threats and the activation of adaptive immunity. As said before, follow-
ing sensing of pathogens by PRRs, activated innate immune cells secrete different 
factors and act as antigen-presenting cells (APCs) to initiate activation of adaptive 
immunity [98]. Thus, it would not be unexpected that trained innate immune 
cells, within their acquired enhanced properties, would be able to induce stronger 
adaptive immune responses [39]. In this regard, BCG vaccine, a well-known trained 
immunity inducer, has shown to enhance the antibody titer and alter heterologous 
T cell responses against a wide range of vaccines and unrelated infections [99–101]. 
In different experimental models, BCG-mediated protection against viral and 
Plasmodium infections was abrogated in the absence of T cells. In these models, BCG 
vaccination has been mainly associated with modulation of CD4+ T helper (Th) 1 
responses. Similar observations have been found in different clinical studies [99]. 
Of note, BCG vaccinated human volunteers displayed a long-lasting heterologous 
Th1 and Th17 response upon stimulation with unrelated pathogens and TLR-ligands 
[38]. To some extent, similar observations have been found in other vaccines such as 
diphtheria-tetanus-pertussis (DTP) or measles vaccine [99].
As said before, trained immunity properties have been recently described also 
for DCs. As being the most professional APCs, they emerge as crucial bridge for 
potentiating adaptive immune responses. In this sense, DCs with high immunos-
timulatory properties that enhance adaptive immune responses via IL-1β release 
had been described [102]. More recently, programmed memory DCs have shown 
to increase Th1/Th17 immunity and confer protection during cryptococcosis [46]. 
Finally, different polybacterial preparations of whole-cell inactivated bacteria, have 
shown to prime DCs and induce enhanced Th1, Th17 and IL-10 T cell responses 
against related and unrelated stimuli [103, 104]. This capability of modulating het-
erologous T cell responses by APCs have been also described to suppress pathogenic 
T cell immunity in experimental models of autoimmune encephalomyelitis [56].
3.2.2 Effector functions on trained innate immune cells
As noted above, a hallmark of trained innate immune cells is the enhancement 
of some effector functions leading to increased non-specific resistance against a 
variety of pathogens. In this regard, β-glucan-trained monocytes show enhanced 
candidacidal activity and efficiently inhibit the C. albicans outgrowth [52]. Production 
of reactive oxygen species (ROS) has shown to be also affected by the induction of 
training. Thus, BCG-trained monocytes [45], β-glucan-trained macrophages [105] or 
β-glucan-trained neutrophils [106] produced increased amount of ROS following dif-
ferent challenges. Finally, increased phagocytosis and production of microbicidal mol-
ecules have been observed in β-glucan-trained macrophages [70, 105]. Mechanisms 
underlying this enhanced effector function could be an intrinsic cell reprogramming 
as consequence of the training, as well as be supported increased expression of dif-
ferent PRRs and surface molecules [45, 60, 87]. Altogether, these enhanced effector 
responses could improve pathogen clearance by increasing host resistance.
On the other hand, a substantial part of the adaptive immune response is 
directed at recruiting other effector cells from the innate immune system to eventu-
ally resolve an infection. Both T helper and B responding cells release cytokines, 
antibodies, and other mediators that activate monocytes, macrophages, NK cells 
or neutrophils to clear extracellular and intracellular pathogens [107]. Multiple 
studies have demonstrated the importance of IFN-γ-mediated priming in the 
activation of macrophages [108, 109], produced by CD4+ Th1 and CD8+ T cells 
[107]. In this sense, it has been previously demonstrated that adaptive T cells render 
innate macrophage memory via IFN-γ-dependent priming [87, 89]. Furthermore, a 
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deep crosstalk between Th17 and neutrophils have been widely demonstrated, via 
production of IL-17 and other related cytokines [110].
Taken into account the potential role of trained innate cells in both the induc-
tion of adaptive and effector responses, a notable amplification loop in the global 
immune response could be considered (Figure 1).
4. Trained immunity-based vaccines
Based on trained immunity pillars, a next generation of anti-infectious vaccines 
has been postulated, coined as ‘Trained Immunity-based Vaccines’ (TIbVs). TIbVs 
would be conceived to confer a broad protection far beyond the antigens they 
contain. By proper targeting of innate immune cells to promote trained immunity, 
a TIbV may confer non-specific resistance to unrelated pathogens while trained 
immunity memory is still present, in addition to the specific response given by 
intrinsic antigens [39].
A bona fide TIbV would consist of two main components: the trained immunity 
inducer(s) and the specific antigen(s). The antigen(s) mission is to generate an 
adaptive (specific) immune response as any conventional vaccine. The trained 
immunity inducers aim to promote the training of innate immune cells. This innate 
immune training would confer non-specific resistance against unrelated pathogens 
for a window of time (months) plus an enhanced adaptive immune response to 
the antigens present in the vaccine itself or from other sources (e.g., coming from 
eventual infections or bystander pathogens) [39].
Two additional concepts arise under the TIbV umbrella: i) trained immunity-
based immunostimulants (TIbIs) and ii) trained-immunity-based adjuvants (TIbAs). 
The former (TIbIs) would induce the training of innate immune cells, so they would 
be ready-to-act against upcoming infections conferring broad non-specific protec-
tion while trained immunity is present, still enhancing adaptive immune responses 
following any eventual natural infection. The latter (TIbAs) would enhance adaptive 
responses against specific antigens incorporated either to the trained inducers as in 
bona fide TIbVs, or in a separated but combined vaccine [39] (Figure 2).
Following the above features, the TIbV concept can be applied to existing anti-
infectious vaccines composed of microorganisms that show heterologous protection 
ascribed to trained immunity.
Figure 1. 
Effect of trained immunity on ongoing immune responses. Induction of trained immunity allows trained cells 
to enhance adaptive immune responses and vice versa, final effector functions of trained cells can be further 
potentiated by enhanced adaptive responses.
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4.1 Available vaccines with heterologous protection against viral infections
During the last decades, robust epidemiological data has demonstrated the role 
of certain vaccines leading to protection against heterologous infection with a high 
impact on overall mortality in children [111–113]. This protection could not only be 
explained by protection achieved by the target disease. Studies on MMR vaccination 
in high-income settings have also evidenced a reduction in non-target infections, 
particularly in respiratory infections [114]. A limitation for most of these epidemio-
logical studies is that they do not identify the agent (viral, bacterium or parasite) 
responsible for the infection. These heterologous effects of certain vaccines confer-
ring non-specific protection for a quite long time are believed to be largely due to 
non-specific stimulation of the innate immune system. It is not yet clear whether 
this is a direct reflection of trained immunity induction (i.e., acting as TIbVs) in 
every case. The fact that most of these vaccines use live-attenuated microorganisms, 
i.e., self-replicating agents, may suggest that a continuous stimulation of innate 
immune cells is necessary to obtain protection and/or to achieve a proper trained 
immunity for this purpose.
4.2 Live attenuated vaccines
4.2.1 BCG
The BCG-Denmark strain was tested in randomized-controlled trials (RCT) 
in infants who normally did not receive the BCG vaccine at birth. These studies 
carried out in Guinea-Bissau demonstrated that vaccination at birth was associated 
Figure 2. 
Different possibilities of trained immunity-based vaccines (TIbVs). Under the umbrella of trained immunity-
based vaccines (TIbVs) different possibilities exist depending on their design and purpose. Bona fide TIbVs are 
those containing both trained immunity inducers and antigens in the same vaccine as occurs in conventional 
vaccines with trained immunity inducing properties. These vaccines show heterologous protection in addition 
to the specific response to the target antigen. TIbIs are intended just to confer non-specific protection by means 
of trained immunity induction beyond the intrinsic antigens they may contain. TIbAs are intended to enhance 
the specific response of other vaccines that are administered later, once trained immunity has been induced, or 
specific antigens combined in the same vaccine as any other adjuvant.
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with lower neonatal mortality, especially due to neonatal sepsis, respiratory infec-
tions, and fever [111, 115]. In these lines, a meta-analysis commissioned by the 
WHO concluded that BCG administration during the first month of life reduces 
all-cause mortality by 30% [116]. In these studies authors did not discriminate the 
etiology of infection (bacterial vs. virus); therefore, a reduction in viral infections 
may explain, to some extent, this result. However, in two studied carried out in 
India in neonates with BCG-Russian strain no such effect was observed [117]; sug-
gesting that different immunological effect of diverse BCG strains may account for 
these discrepancies. A study carried out in infants to assess the impact of BCG vac-
cination on the incidence of RSV infection suggested a possible protective role for 
BCG vaccination against acute lower respiratory tract infection [118]. Other clinical 
studies have provided evidence suggesting a protective role for BCG on secondary 
viral infections [79]. In this regard, the impact of BCG vaccination on viral infec-
tion in human healthy volunteers has been assessed using the live attenuated yellow 
fever vaccine (YFV) as a model of viral human infection [76]. BCG vaccination 
induced epigenetic reprogramming in human monocytes, and these modifications 
correlated with IL-1β upregulation and the reduction of viremia, all these features 
being the hallmarks of trained immunity [76].
Similar protective effect of BCG was observed in several studies in elderly 
people regarding respiratory tract infections. BCG vaccination in subjects of 
60–75 years old once a month for three consecutive months resulted in reduction 
of acute upper respiratory tract infection, concomitant to significant increase in 
IFN-γ and IL-10 compared with those receiving placebo [119]. A recent random-
ized trial of BCG vaccination was carried out in elderly patients (age ≥ 65 years) 
returning home from hospital admission, these subjects are at high risk to develop 
infections. The BCG vaccination increased the time to first infection (primary 
outcome) and decreased the incidence of a new infection [120]. Besides, results 
demonstrated that BCG vaccination resulted in lower number of infections of all 
causes, especially respiratory tract infections of probable viral origin, although no 
discrimination was made between respiratory tract infections caused by bacteria or 
viruses.
BCG has also been shown to enhance the response to vaccines directed against 
viral infections [79]. A clinical study in healthy volunteers demonstrated that BCG 
administration prior to influenza vaccination increases antibody titers against 
the 2009 pandemic influenza A (H1N1) vaccine strain, concomitantly with an 
enhanced IFN-γ production to influenza antigens compared with the control 
group [121].
4.2.2 Influenza vaccine
The cold-adapted, live attenuated influenza vaccine (CAIV) has been shown 
to provide non-specific cross-protection against RSV in an experimental model of 
infection [122].
In a randomized pilot study conducted in healthy volunteers receiving a trivalent 
influenza vaccine, cytokine responses against unrelated pathogens were observed 
[121]. During the 2003–2004 influenza A (H3N2) outbreak, an open-labeled, 
nonrandomized vaccine trial was carried out in children 5 to 18 years old. Subjects 
received either trivalent live attenuated or inactivated influenza vaccine. Live 
attenuated influenza vaccine but not trivalent inactivated vaccine was effective in 
children administered during influenza outbreak, despite the dominant circulating 
influenza virus was antigenically different from the vaccine strain [123].
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4.2.3 Measles vaccine
Measles vaccine (MV) is among the live vaccines that have been shown to 
have beneficial effects reducing all-cause mortality [124]. Randomized clinical 
trials and observational studies from low-income countries have concluded that 
measles vaccination is associated with decreased overall mortality and morbidity 
[100]. However, a systematic review carried out by Higgins and colleagues has 
pointed out that most of these studies were considered at high risk of bias [116]. 
Nevertheless, MV seems to induce a transient suppressive effect on both the lym-
phoproliferative and innate response evaluated in peripheral blood mononuclear 
cells (PBMCs) from children, with slight increase in innate immune response, 
measured by non-specific cytokine production [100]. It has been reported that 
following measles vaccination, the ex vivo production of both innate (IL-6 and 
TNF-α) and adaptive (IFN-γ and IL-2) cytokines decreases for 2 weeks, but levels 
of IL-2, IL-6 and IFN-γ are increased at day 30 post vaccination compared with 
baseline [125]. Differences in males and females have been reported, where girls 
seem to receive stronger beneficial effects. In this regard, a study of MV-specific 
innate responses following MMR vaccination found higher TNFα, IL-6 and IFN-α 
secretion, cytokines associated to trained immunity, in adolescent girls than 
boys [126].
4.2.4 Oral polio vaccine
There are currently only three countries where polio remains endemic. Thus, 
polio-free, high income countries are introducing the use of the inactivated polio 
vaccine (IPV). However, there are still many countries that use the live-attenuated 
oral polio vaccine (OPV). Despite current WHO policy to replace OPV by IPV, there 
is epidemiological evidence that supports that replacing OPV by IPV might have an 
impact on overall mortality [96], since OPV has shown strong non-specific benefi-
cial effects even in settings where the incidence of the targeted infection is low. In 
this regard, campaigns to eliminate polio in West Africa have been associated with 
lower child mortality rates [127].
4.3 Inactivated vaccines
As pointed above, most of the vaccines described so far showing non-specific 
heterologous effects contain live-attenuated microorganisms. Nevertheless, 
fully inactivated bacterial vaccines have also been described conferring protec-
tion against viral infections, and some of them for a fairly long period of time. 
Interestingly, these vaccines are mucosal preparations that are administered daily 
for long periods of time (weeks/months) rather than single, or seldom, doses used 
in live attenuated vaccines. Thus, it seems that the much longer administration of 
these inactivated mucosal vaccines resembles the effect achieved by live vaccines on 
heterologous protection associated to trained immunity (Figure 3).
4.3.1 Polybacterial whole-cell vaccines
These vaccines are used for the prevention of recurrent infections in susceptible 
subjects, mainly associated to the respiratory and urogenital tracts [128–134]. Since 
they target infections occurring in these tracts, their administration is generally 
through mucosal tissues to obtain a better mucosal response [135, 136].
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MV130 is a sublingual vaccine used to prevent recurrent respiratory tract 
infections [128, 129] containing inactivated whole-cell bacteria that are common 
pathogens in the airways. Its ability immunomodulating DCs has been addressed 
experimentally in vitro and in vivo. MV130 triggers the release of cytokines 
ascribed to trained immunity in different setting, including TNF-α, IL-1β and 
IL-6 [103, 137, 138]. Sublingual immunization of mice with MV130 induces a 
systemic Th1/Th17 and IL-10 enhanced responses against unrelated antigens 
[103]. Similar enhancement was shown in patients treated with MV130 where 
an increased T cell response to flu antigens were described [128]. MV130 was 
successfully used in infants with recurrent wheezing, a condition triggered in 
most cases by viral infections. It is noteworthy that the protective effect was also 
shown 6 months after discontinuation of treatment, which points to a long-
lasting effect that fits with the memory ascribed to trained immunity (Nieto 
et al., under review). In this regard, MV130 has been shown to induce trained 
immunity and to confer protection against experimental virus infections (Brandi 
et al., under review). Recent studies have assessed the clinical benefit of MV130 
as a TIbV in the context of recurrent respiratory infections in vulnerable popula-
tions such as patients with different primary and secondary immunodeficiencies 
showing a reduced rate of respiratory infections [130, 139] (Ochoa-Grullón et 
al., in press).
4.3.2 Polybacterial lysates
Although not considered vaccines but immunostimulants, these bacterial 
preparations are, like MV130, used for the prevention of recurrent respiratory 
infections. OM-85, one of the best studied, is composed of chemically treated bacte-
rial lysates for oral administration, acting through the gastro-intestinal mucosa. 
OM-85 has been shown to be effective in experimental viral infections [140] and in 
children with recurrent wheezing [141], a condition triggered by viruses as noted 
above. OM-85 stimulates the release of proinflammatory cytokines such as IL-1β, 
TNF-α and IL-6 by macrophages [142], typical of trained immunity induction, as 
well as Th1 cytokines including IFN-γ [143]. It is not known, however, the role of 
trained immunity in their mechanism of protection. A recent study conducted in 
infants, the observed protection against respiratory infections under OM-85 treat-
ment stopped when treatment was discontinued [144], which may point against the 
memory ascribed to trained immunity.
Figure 3. 
Trained immunity window by self-replicating and inactivated TIbVs. Trained immunity-based vaccines 
(TIbVs) containing live-attenuated self-replicating microorganisms (e.g. BCG) may require fewer 
administrations to induce an adequate trained immunity window of sufficient intensity, quality and/or 
duration than vaccines with dead microorganisms. Fully-inactivated TIbVs can be enhanced to induce trained 
immunity with a multiple dose schedule (e.g. MV130).
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4.4 The potential clinical applications of TIbVs in the context of viral outbreaks
The non-specific mechanism of TIbVs against widely differing pathogens associ-
ated to the induction of trained immunity can be exploited clinically. This makes 
TIbVs as a ready-to-act tool to tackle disease outbreaks from different angles where 
conventional specific vaccines have proven their limitations:
Newly emerging disease outbreaks, with no conventional vaccines available. Even in 
the presence of therapeutic options, vaccines are the best tool to prevent infections. 
However, even with worldwide efforts, getting a vaccine to the public takes time. 
In addition, side effects, dosing issues, and manufacturing problems can all cause 
delays [3]. Herein, using available TIbVs could mitigate the devastating conse-
quences of emergent outbreaks by means of non-specific protection, until a suitable 
specific vaccine is available.
Newly emerging disease outbreaks, first coming vaccines with partial efficacy. Even 
if a vaccine gets available to the market, conventional strategies might raise some 
issues. The unpredictable identity of largely unknown emerging pathogens, the 
lack of appropriate experimental animal models, and the time for faster develop-
ing may give raise to an upcoming vaccine with no full efficacy [3]. On the other 
hand, limitations of current vaccines, such as mumps, also include a low efficacy 
resulting from an unacceptable drop in the immune response over time, requiring 
re-immunization [145]. In these contexts, the administration of a TIbV prior to the 
specific vaccine may enhance the response to the latter (111).
Re-emerging disease outbreaks, pathogens with high mutation rates and loss of vac-
cine efficacy. Mutations are the building blocks of evolution in any organism. Viruses 
are among the fastest evolving entities, especially RNA viruses such as influenza. 
Implications in conventional vaccine design are numerous, as a high mutation rate 
makes it hard to design a vaccine that is universally effective across many years. As 
a result, this makes a vaccine effective for shorter and raises the need for yearly vac-
cination programs [22, 146]. Since the underlying mechanism of TIbVs extend well 
beyond their nominal antigens and have a broad-spectrum of protection, TIbVs 
could overcome the troublesome of highly specific vaccines that promote antigen 
variant switching [147].
Disease outbreaks in vulnerable populations. During infectious disease outbreaks, 
vulnerable populations are usually disproportionately affected due to an interplay of 
immunological, epidemiological, and medical factors, which leads to sub-optimal or 
even under-vaccination [148]. This is well exemplified in the elderly population, where 
successful vaccination against important infectious pathogens which cause high mor-
bidity and mortality represents a growing public health priority. Age-related immu-
nosenescence and ‘inflammaging’ have been postulated as underlying mechanisms 
responsible for decreased response and high mortality, including during COVID-19 
pandemic or influenza season [80, 149]. Therefore, more potent vaccines are needed. 
In this regard, the induction of trained immunity by the use of TIbVs is proposed to 
overcome the immune dysfunction found in these individuals [28]. Thus, elderly has 
been proposed as one of the groups to benefit from the use of TIbVs, including severe 
COVID-19 disease, with the aim of potentiating the immunogenicity of their vaccina-
tion [80]. Moreover, some types of immunodeficiencies or immunosuppression may 
benefit from TIbVs. These formulations, by means of tackling both branches of immu-
nity, especially the innate compartment, may be an achievable alternative to reinforce 
protection or optimize immunogenicity of vaccination in this population [130, 139].
Altogether, harnessing the TIbV concept has been suggested as a crucial step in 
future vaccine development and implementation, because a wide range of clinical 
applications may benefit to some extent from their use [150].
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4.5 TIbVs in the time of COVID-19
Despite the tremendous financial and scientific effort invested to rapidly obtain 
a prophylactic vaccine against SARS-CoV-2, only the first one has been licensed in 
December 2020. Although this means less than a year since the declaration of the 
pandemic by the WHO, which is an unprecedented achievement, in the meantime, 
two pandemic waves of COVID-19 and more than 1.5 million deaths have been 
declared worldwide. Therefore, alternative strategies have been considered to fill 
the gap until a safe and effective vaccine is available. As noted earlier in this chapter, 
TIbVs can play an important role for this purpose by increasing host resistance to 
other pathogens, including viruses.
A bunch of recent studies have been published supporting the role of certain 
vaccines, including BCG, OPV and measles, as a possible successful strategy to 
reduce susceptibility and severity to SARS-CoV-2 through trained immunity induc-
tion [80, 151, 152]. Thus, clinical trials are currently being conducted to find out the 
contribution of trained immunity as a preventive tool in the context of COVID-19 
pandemics [153]. In a prospective observational trial, 255 MMR vaccinated subjects 
were followed searching for COVID-19 cases, thirty-six presented COVID-19 but all 
with a remarkable mild course [154]. Recent studies have also suggested a potential 
benefit of influenza vaccine on the susceptibility and the outcome of certain infec-
tions including SARS-CoV-2. In this sense, a particular attention has been focused 
on a high-risk population, the elderly. In a study conducted in Italy, influenza 
vaccination in people aged 65 and over was associated with a reduced spread and a 
less severe clinical expression of COVID-19 [155].
Finally, in addition to the potential role of TIbV conferring resistance against 
SARS-CoV-2 infection, they can eventually be used to increase efficacy of specific 
anti-COVID-19 vaccines, when available, especially in vulnerable population. In 
this sense, implications of vaccination route and mucosal immunity have also been 
raised as a key aspect in the development of safe and effective prophylaxis interven-
tions against SARS-CoV-2. Most formulations in development are parentally admin-
istered; only a few COVID-19 vaccine candidates are administered by mucosal 
routes. Still, studies indicate that even if mucosal immunization against coronavirus 
does not confer sterilizing immunity, the ability to induce anti-SARS-CoV-2 IgA 
responses in the airways may prevent virus spread to the lung and avoid respiratory 
distress [156]. In this regard, mucosal TIbVs could enhance the mucosal response of 
specific COVID-19 vaccines acting as TIbAs by combining them as pointed above in 
those especially vulnerable subjects.
5. Conclusions and future perspectives
Viral outbreaks can cause epidemics and pandemics if the route of transmission 
allows for the rapid virus spread. Given the ease of travel and the global exchange 
of potential transmitting agents, these situations will be increasingly frequent in 
the future. Preventing the spread of a virus outbreak caused by a highly contagious 
agent is not easy in the absence of effective therapies or preventive measures. 
Although the development of effective prophylactic vaccines specific for the threat-
ening virus is the final goal when possible, this requires a minimum time of almost 
a year in the best possible scenario. Meanwhile, the consequences of the spread of 
a deadly virus can be devastating, as it is exemplified during the COVID-19 pan-
demic. This scenario may also take place in the case of re-emerging viruses tackled 
by partial efficacious vaccines. In such situations, harnessing the heterologous 
non-specific protection of some existing vaccines with a known safety track record 
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is an interesting possibility. This protection may be critical for vulnerable subjects 
and/or for highly exposed individuals, like healthcare workers.
Non-specific protection of some vaccines is thought to be mainly dependent on 
their effect on the innate immune system. Increasing evidence gathered over the 
past few years points that innate immune cells show memory-like features when 
properly activated. This memory termed “trained immunity” has been associated 
with the non-specific protection of vaccines. The concept of “trained immunity-
based vaccine” (TIbV) has been drawn to exploit the potential of trained immunity 
in designing novel vaccines or to redefine bacterial-derived preparations conferring 
broad protection against widely differing pathogens. As trained immunity may 
have implications on the adaptive immune response and vice-versa, its potential to 
provide enhanced immune responses is quite broad whether considering natural 
infections or following vaccination.
Taken advantage of the current COVID-19 pandemic, a number of clinical trials 
have been launched with putative TIbVs in order to address protection in highly 
exposed subjects. The results are eagerly expected as these initiatives may be con-
sidered as a proof-of-concept supporting their use in future epidemics/pandemics 
to fill the gap until a specific vaccine is available. Nevertheless, as trained immunity 
can be achieved by different inducers, it is unlikely to obtain the same degree of 
protection, duration, etc. for all of them, which may also depend on the biological 
behavior and the route of transmission of the threatening pathogen. As in most 
instances rapidly spreading viruses are airborne and primarily infect the mucosa 
of the airway tract, induction of trained immunity at the local mucosal level can 
confer a more adequate protection. This may be an opportunity for mucosal TIbVs 
as compared to those given parenterally.
Trained immunity may justify heterologous protection of vaccines, help to 
explain their underlying mechanisms, open avenues for next generation of vaccines, 
or be proposed to tackle outbreaks by new pathogens as described here. However, 
this is an emerging field that requires more clinical data before being a reality in 
the clinical practice; not only to be used against infectious outbreaks, but to fight 
against recurrent infections in vulnerable subjects for whom no effective vaccines 
are yet available.
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